AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company’s surgical nerve repair solutions include Avance Nerve Graft, a proprietary processed nerve allograft for bridging severed nerves without the comorbidities associated with a nerve autograft surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. It also offe...
13631 Progress Boulevard
Alachua, FL 32615
AxoGen, Inc. Announces Resignation of John Harper as a Member of the Board of Directors, Effective as of December 31, 2015
Dec 15 15
AxoGen, Inc. announced that on December 11, 2015, John Harper delivered to notice of his resignation as a member of the Board of Directors of the company effective as of December 31, 2015.
Xogen, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Revises Earnings Guidance for the Full Year 2015
Nov 6 15
AxoGen, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported revenues of $8,153,675 against $4,671,340 a year ago. Loss from operations was $1,917,826 against $1,802,904 a year ago. Net loss was $2,978,858 against $3,238,174 a year ago. Loss Per basic and diluted share was $0.11 against $0.19 a year ago.
For the nine months, the company reported revenues of $19,522,244 against $12,023,789 a year ago. Loss from operations was $6,614,799 against $7,091,791 a year ago. Net loss was $9,744,932 against $11,219,210 a year ago. Loss Per basic and diluted share was $0.39 against $0.64 a year ago. Net cash used for operating activities was $8,790,266 against $8,019,485 a year ago. Purchase of property and equipment was $353,093 against $342,875 a year ago. Acquisition of intangible assets was $92,184 against $39,454 a year ago.
The company announced that based on the strong growth in the first nine months of 2015 and continued sales momentum in the third quarter, the company is raising its revenue guidance and now expects 2015 full year revenue to be greater than $26.5 million with annual gross margins in the high 70% range.
AxoGen, Inc. to Report Q3, 2015 Results on Nov 05, 2015
Oct 16 15
AxoGen, Inc. announced that they will report Q3, 2015 results After-Market on Nov 05, 2015